<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PATANOL - olopatadine hydrochloride solution/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is 
a sterile ophthalmic solution containing olopatadine, a relatively selective 
H<span class="Sub">1</span>-receptor antagonist and inhibitor of histamine release 
from the mast cell for topical administration to the eyes. Olopatadine 
hydrochloride is a white, crystalline, water-soluble powder with a molecular 
weight of 373.88. The chemical structure is presented below:</p>
<p><img alt="imae of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae8b4a9d-4308-4a3c-8ec9-1e8d9060db68&amp;name=Patanol-01.jpg"></p>
<p><span class="Bold">Chemical 
Name:</span>11-[(Z)-3-(Dimethylamino)propylidene]-6-11-dihydrodibenz[b,e]oxepin-2-acetic 
acid hydrochloride.</p>
<p>Each mL of PATANOL contains: <span class="Bold">Active:</span> 1.11 mg 
olopatadine hydrochloride equivalent to 1 mg olopatadine. <span class="Bold">Preservative:</span> benzalkonium chloride 0.01%. <span class="Bold">Inactives:</span> dibasic sodium phosphate; sodium chloride; 
hydrochloric acid/sodium hydroxide (adjust pH); and purified water. It has a pH 
of approximately 7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 300 mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Olopatadine is an inhibitor of the release of histamine from the 
mast cell and a relatively selective histamine H<span class="Sub">1</span>-antagonist that inhibits the <span class="Italics">in vivo 
</span>and <span class="Italics">in vitro</span> type 1 <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity</span> 
reaction including inhibition of histamine induced effects on human conjunctival 
epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, 
dopamine, and muscarinic type 1 and 2 receptors. Following topical ocular 
administration in man, olopatadine was shown to have low systemic exposure. Two 
studies in normal volunteers (totaling 24 subjects) dosed bilaterally with 
olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks 
demonstrated plasma concentrations to be generally below the quantitation limit 
of the assay (&lt;0.5 ng/mL). Samples in which olopatadine was quantifiable were 
typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The 
half-life in plasma was approximately 3 hours, and elimination was predominantly 
through renal excretion. Approximately 60-70% of the dose was recovered in the 
urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were 
detected at low concentrations in the urine.</p>
<p>Results from an environmental study demonstrated that PATANOL was effective 
in the treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> when dosed 
twice daily for up to 6 weeks. Results from conjunctival antigen challenge 
studies demonstrated that PATANOL, when subjects were challenged with antigen 
both initially and up to 8 hours after dosing, was significantly more effective 
than its vehicle in preventing <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> associated with allergic 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is 
indicated for the treatment of the signs and symptoms of allergic 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is 
contraindicated in persons with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to olopatadine 
hydrochloride or any components of PATANOL.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is 
for topical use only and not for injection or oral use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>Information for Patients<p class="First">To prevent contaminating the dropper tip and solution, care 
should be taken not to touch the eyelids or surrounding areas with the dropper 
tip of the bottle. Keep bottle tightly closed when not in use.</p>
<p>Patients should be advised not to wear a contact lens if their eye is red. 
PATANOL® should not be used to treat contact lens-related irritation. The 
preservative in PATANOL, benzalkonium chloride, may be absorbed by soft contact 
lenses. Patients who wear soft contact lenses and <span class="Bold">whose eyes 
are not red</span> should be instructed to wait at least ten minutes after 
instilling PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% before 
they insert their contact lenses.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Olopatadine administered orally was not carcinogenic in mice and 
rats in doses up to 500mg/kg/day and 200mg/kg/day, respectively. Based on a 40 
µl drop size, these doses were 78,125 and 31,250 times higher than the maximum 
recommended ocular human dose (MROHD). No mutagenic potential was observed when 
olopatadine was tested in an <span class="Italics">in vitro</span> bacterial 
reverse mutation (Ames) test, an <span class="Italics">in vitro</span> mammalian 
chromosome aberration assay or an <span class="Italics">in vivo</span> mouse 
micronucleus test. Olopatadine administered to male and female rats at oral 
doses of 62,500 times MROHD level resulted in a slight decrease in the fertility 
index and reduced implantation rate; no effects on reproductive function were 
observed at doses of 7,800 times the maximum recommended ocular human use 
level.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<p><span class="Bold">Pregnancy Category C.</span> Olopatadine was 
found not to be teratogenic in rats and rabbits. However, rats treated at 600 
mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 
62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. 
There are, however, no adequate and well-controlled studies in pregnant women. 
Because animal studies are not always predictive of human responses, this drug 
should be used in pregnant women only if the potential benefit to the mother 
justifies the potential risk to the embryo or fetus.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Olopatadine has been identified in the milk of nursing rats 
following oral administration. It is not known whether topical ocular 
administration could result in sufficient systemic absorption to produce 
detectable quantities in the human breast milk. Nevertheless, caution should be 
exercised when PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is 
administered to a nursing mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in pediatric patients below the age of 3 
years have not been established.</p>
<a href="http://"></a><a href="http://"></a>Geriatric Use<p>No overall differences in safety or effectiveness have been 
observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> have been reported at an incidence of 7%. The following 
adverse experiences have been reported in less than 5% of patients: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, 
<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> syndrome, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, foreign body 
sensation, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>. Some of these 
events were similar to the underlying disease being studied.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one drop in each affected eye two times 
per day at an interval of 6 to 8 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is 
supplied as follows: 5 mL in plastic DROP-TAINER® dispenser.</p>
<p>          5 mL: <span class="Bold">NDC</span>  54868-4528-0</p>
<a href="http://"></a><a href="http://"></a><br>Storage<p>Store at 39°F-77°F (4°C-25°C).</p>
<p><span class="Bold">Rx Only</span></p>
<p><br></p>
<p>U.S. Patent Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805.</p>
<p>© 2000, 2003, 2005 Alcon, Inc.</p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span><br>Fort Worth, Texas 76134 
USA</p>
<p>Printed in USA</p>
<br><span class="Bold">Relabeling of "Additional" label by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1%</p>
<p>5 mL</p>
<p>NDC 54868-4528-0</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ae8b4a9d-4308-4a3c-8ec9-1e8d9060db68&amp;name=4528.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PATANOL 		
					</strong><br><span class="contentTableReg">olopatadine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4528(NDC:0065-0271)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLOPATADINE HYDROCHLORIDE</strong> (OLOPATADINE) </td>
<td class="formItem">OLOPATADINE HYDROCHLORIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4528-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020688</td>
<td class="formItem">05/08/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>179b7b73-1458-4d3e-9f29-84e3ffe14c7d</div>
<div>Set id: ae8b4a9d-4308-4a3c-8ec9-1e8d9060db68</div>
<div>Version: 1</div>
<div>Effective Time: 20110512</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
